This highlights the potential for receptor tyrosine kinase fusions like ROS1 to develop as acquired alterations in NSCLC, underscoring the importance of persistent molecular re-profiling to guide appropriate targeted therapy. Here, NTRK1 is linked to non-small cell lung carcinoma.